CONCLUSION

MagicTouch Sirolimus coated balloon demonstrated safety and efficacy in real world patients.

The clinical outcomes in complex patient cohorts are very encouraging warrants the use of SCB in complex patients too.

  • Principal Investigator
    Dr. Sameer Dani,
    Life Care Institute of Medical Sciences and Research, India
STUDY DESIGN

• Purpose of this registry is to evaluate the safety and efficacy of Sirolimus Coated Balloon in the patients with Coronary Artery Disease.
• Prospective, Multi‐center clinical registry enrolls real world, all comers patients
• Clinical Follow-up at 1,6 and 12 Months.

Study Endpoint:

Primary Endpoints:
MACE (Major Adverse Cardiac Event) is a composite of cardiac death, target vessel myocardial infarction (TV-MI) and target lesion/vessel revascularization (TLR/TVR) at 6 months.

Secondary Endpoint:
MACE (Major Adverse Cardiac Event) is a composite of cardiac death, target vessel myocardial infarction (TV-MI) and target lesion/vessel revascularization (TLR/TVR) at 12 months.

PATIENTS’ BASELINE CHARACTERISTICS
LESION AND PROCEDURAL DETAILS
CUMULATIVE CLINICAL OUTCOMES UPTO 2-YEARS
CLINICAL EVIDENCE IN COMPLEX COHORTS @1-YEAR